Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Alcohol Use Disorder With Depressive Symptoms
NCT07638553Phase 3Recruiting
- Sponsor
- CHU Nîmes
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of psilocybin in alcohol use disorder (AUD) (2 arms), sponsored by CHU Nîmes. Primary endpoints: Incidence of relapse between groups at 6 months and Time to relapse between groups at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07638553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638553.